Skip to main content
Taylor & Francis Group Logo
Advanced Search

Click here to search books using title name,author name and keywords.

  • Login
  • Hi, User  
    • Your Account
    • Logout
Advanced Search

Click here to search books using title name,author name and keywords.

Breadcrumbs Section. Click here to navigate to respective pages.

Chapter

- Actions of N-Acetylcysteine in the Central Nervous System: Implications for the Treatment of Neurodegenerative and Neuropsychiatric Disorders

Chapter

- Actions of N-Acetylcysteine in the Central Nervous System: Implications for the Treatment of Neurodegenerative and Neuropsychiatric Disorders

DOI link for - Actions of N-Acetylcysteine in the Central Nervous System: Implications for the Treatment of Neurodegenerative and Neuropsychiatric Disorders

- Actions of N-Acetylcysteine in the Central Nervous System: Implications for the Treatment of Neurodegenerative and Neuropsychiatric Disorders book

- Actions of N-Acetylcysteine in the Central Nervous System: Implications for the Treatment of Neurodegenerative and Neuropsychiatric Disorders

DOI link for - Actions of N-Acetylcysteine in the Central Nervous System: Implications for the Treatment of Neurodegenerative and Neuropsychiatric Disorders

- Actions of N-Acetylcysteine in the Central Nervous System: Implications for the Treatment of Neurodegenerative and Neuropsychiatric Disorders book

Edited ByCon Kerry Kenneth Stough, Andrew Scholey
BookAdvances in Natural Medicines, Nutraceuticals and Neurocognition

Click here to navigate to parent product.

Edition 1st Edition
First Published 2013
Imprint CRC Press
Pages 14
eBook ISBN 9780429111761

ABSTRACT

N-Acetylcysteine (NAC) is the N-acetyl derivative of cysteine, and is less reactive, less toxic, and less susceptible to oxidation than cysteine, as well as being more soluble in water. For these reasons it is a better source of cysteine than the parenteral administration of cysteine itself [1]. NAC is rapidly absorbed, with time to peak plasma levels (tmax) being 1.4 ± 0.7 h following oral administration. The average

Pharmacokinetics .....................................................................................................29 NAC in the Treatment of Dementia .........................................................................30

T&F logoTaylor & Francis Group logo
  • Policies
    • Privacy Policy
    • Terms & Conditions
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
    • Cookie Policy
  • Journals
    • Taylor & Francis Online
    • CogentOA
    • Taylor & Francis Online
    • CogentOA
  • Corporate
    • Taylor & Francis Group
    • Taylor & Francis Group
    • Taylor & Francis Group
    • Taylor & Francis Group
  • Help & Contact
    • Students/Researchers
    • Librarians/Institutions
    • Students/Researchers
    • Librarians/Institutions
  • Connect with us

Connect with us

Registered in England & Wales No. 3099067
5 Howick Place | London | SW1P 1WG © 2021 Informa UK Limited